LPAR1 and myeloid sarcoma: These data combine to suggest that an LPA1 antagonist may enable a multipronged approach towards disease treatment, and that the identification of a potent, selective, brain penetrant LPA1 antagonist could make a significant impact on the treatment of inflammatory demyelinating diseases such as MS.